Brief: Xbrane Provides Update On Subsidiary Primm Pharma

Xbrane Biopharma AB

17/02/2022 07:09

Feb 17 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * XBRANE PROVIDES AN UPDATE ON ITS SUBSIDIARY PRIMM PHARMA
    * PRIMM PHARMA S.R.L IS CASH-FLOW POSITIVE AS OF Q4 2021 ON
BACK
OF ROYALTIES FROM OUT-LICENSE OF IP AND PRODUCTION EQUIPMENT
    * EFFORTS TO DIVEST SUBSIDIARY CONTINUES
    * NEGOTIATIONS WITH PREVIOUSLY EXPECTED ACQUIRER NEWFADEM
S.R.L
FOR TIME BEING HAS BEEN PAUSED

Source text for Eikon:  ID:nMFN92XwrH 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))